'Fast-Fail' AI Blood Test Offers Rapid Assessment for Pancreatic Cancer Treatment Response

A groundbreaking AI-based blood test, developed by researchers at Johns Hopkins University School of Medicine, shows promise for improving the management of pancreatic cancer. This innovative technique, named ARTEMIS-DELFI, detects DNA fragments shed by tumors into the bloodstream, enabling clinicians to swiftly evaluate whether treatments are effective. Unlike traditional imaging methods that can be delayed or less accurate, especially with immunotherapies, this blood test provides a quicker and potentially more reliable indication of treatment response.

The study involved testing ARTEMIS-DELFI in blood samples from patients enrolled in two significant clinical trials focused on pancreatic cancer therapies. Results demonstrated that this approach could predict therapeutic responses with greater accuracy than existing markers, and it did so as early as four weeks after starting treatment. When compared to another method called WGMAF, which analyzes tumor mutations, ARTEMIS-DELFI proved to be simpler, more broadly applicable, and more effective, particularly because it could include more patients and was easier to implement.

The importance of such rapid assessment tools cannot be overstated in pancreatic cancer cases, where diagnosis often occurs at advanced stages with swift disease progression. Dr. Victor E. Velculescu, senior author of the study, emphasized the urgency: “Providing patients with faster insights into therapy effectiveness allows for quicker treatment adjustments, which could significantly impact outcomes.”

Current monitoring relies heavily on imaging, which can be time-consuming and less precise, especially with immune-based treatments. The new method uses machine learning to analyze cell-free DNA fragments in blood samples, circumventing some of the limitations of tissue biopsies and imaging. This approach was validated in a second clinical trial called PACTO, confirming its ability to identify responders within four weeks.

Lead researcher Carolyn Hruban highlighted the potential of this approach in changing pancreatic cancer care: “It’s simpler, likely less expensive, and more widely applicable than traditional tissue-based methods.” Looking ahead, the research team plans prospective studies to examine whether ARTEMIS-DELFI can help tailor treatments more effectively, not just for pancreatic cancer but for other types as well. Their earlier work in colon cancer showed similar promise, indicating a broad potential for cell-free DNA fragmentation analysis in cancer therapy monitoring.

Overall, this cell-free DNA fragmentation analysis offers a real-time, non-invasive way to personalize cancer treatment, aiming to improve patient outcomes through more timely and accurate therapy assessments.

Source: https://medicalxpress.com/news/2025-05-fast-ai-blood-patients-pancreatic.html